Loading...
Reach Banner
Keywords
Last name
Institution

Valerie Waters

TitleStaff Physician
InstitutionThe Hospital for Sick Children
DepartmentInfectious Diseases
Address555 University Avenue
Toronto ON M5G 1X8
Phone416-813-1500
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Stapleton PJ, Izydorcyzk C, Clark S, Blanchard A, Wang PW, Yau Y, Waters V, Guttman DS. Pseudomonas aeruginosa Strain-sharing in Early Infection Among Children With Cystic Fibrosis. Clin Infect Dis. 2021 11 02; 73(9):e2521-e2528. PMID: 32544950.
      View in: PubMed
    2. Guttman K, Wang P, Jackson L, Morris A, Yau Y, Waters V. Isolation of Total RNA from Pseudomonas aeruginosa within Biofilms for Measuring Gene Expression. J Vis Exp. 2021 09 24; (175). PMID: 34633367.
      View in: PubMed
    3. Waters V. Two Steps Forward: Improving the Management of Cystic Fibrosis Pulmonary Exacerbations. Am J Respir Crit Care Med. 2021 Sep 20. PMID: 34543576.
      View in: PubMed
    4. Morris AJ, Jackson L, Cw Yau Y, Reichhardt C, Beaudoin T, Uwumarenogie S, Guttman KM, Lynne Howell P, Parsek MR, Hoffman LR, Nguyen D, DiGiandomenico A, Guttman DS, Wozniak DJ, Waters VJ. The role of Psl in the failure to eradicate Pseudomonas aeruginosa biofilms in children with cystic fibrosis. NPJ Biofilms Microbiomes. 2021 08 04; 7(1):63. PMID: 34349133.
      View in: PubMed
    5. Waters V. Beneath the surface: assessing cystic fibrosis pulmonary infections in the era of highly effective modulator therapy. J Cyst Fibros. 2021 09; 20(5):723-724. PMID: 34275758.
      View in: PubMed
    6. Stanojevic S, Davis SD, Perrem L, Shaw M, Retsch-Bogart G, Davis M, Jensen R, Clem CC, Isaac SM, Guido J, Jara S, France L, McDonald N, Solomon M, Sweezey N, Grasemann H, Waters V, Sanders DB, Ratjen FA. Determinants of lung disease progression measured by lung clearance index in children with cystic fibrosis. Eur Respir J. 2021 07; 58(1). PMID: 33542049.
      View in: PubMed
    7. Kakalia S, Chakravarty A, Manson D, Lam R, Waters V, Kitai I. Choosing Wisely: Computed Tomography in the Diagnosis of Adolescents With Intrathoracic Tuberculosis. J Pediatric Infect Dis Soc. 2021 Apr 30; 10(4):521-524. PMID: 33245122.
      View in: PubMed
    8. Clark ST, Stapleton PJ, Wang PW, Yau YCW, Waters VJ, Hwang DM, Guttman DS. Evaluation of digital dispense-assisted broth microdilution antimicrobial susceptibility testing for Pseudomonas aeruginosa isolates. Sci Rep. 2021 04 28; 11(1):9157. PMID: 33911107.
      View in: PubMed
    9. Perrem L, Stanojevic S, Shaw M, Jensen R, McDonald N, Isaac SM, Davis M, Clem C, Guido J, Jara S, France L, Solomon M, Grasemann H, Waters V, Sweezey N, Sanders DB, Davis SD, Ratjen F. Lung Clearance Index to Track Acute Respiratory Events in School-Age Children with Cystic Fibrosis. Am J Respir Crit Care Med. 2021 04 15; 203(8):977-986. PMID: 33030967.
      View in: PubMed
    10. Martin I, Waters V, Grasemann H. Approaches to Targeting Bacterial Biofilms in Cystic Fibrosis Airways. Int J Mol Sci. 2021 Feb 22; 22(4). PMID: 33671516.
      View in: PubMed
    11. Kwong K, Benedetti A, Yau Y, Waters V, Nguyen D. Failed eradication therapy of new onset Pseudomonas aeruginosa infections in cystic fibrosis children is associated with bacterial resistance to neutrophil functions. J Infect Dis. 2021 Feb 19. PMID: 33606875.
      View in: PubMed
    12. Morris AJ, Li A, Jackson L, Yau YCW, Waters V. Quantifying the Effects of Antimicrobials on In vitro Biofilm Architecture using COMSTAT Software. J Vis Exp. 2020 12 14; (166). PMID: 33369598.
      View in: PubMed
    13. Khanolkar RA, Clark ST, Wang PW, Hwang DM, Yau YCW, Waters VJ, Guttman DS. Ecological Succession of Polymicrobial Communities in the Cystic Fibrosis Airways. mSystems. 2020 Dec 01; 5(6). PMID: 33262240.
      View in: PubMed
    14. Somayaji R, Yau YCW, Tullis E, LiPuma JJ, Ratjen F, Waters V. Clinical Outcomes Associated with Burkholderia cepacia Complex Infection in Patients with Cystic Fibrosis. Ann Am Thorac Soc. 2020 12; 17(12):1542-1548. PMID: 32678679.
      View in: PubMed
    15. Jackson L, Waters V. Factors influencing the acquisition and eradication of early Pseudomonas aeruginosa infection in cystic fibrosis. J Cyst Fibros. 2021 01; 20(1):8-16. PMID: 33172756.
      View in: PubMed
    16. Waters VJ, Baertschiger RM, Kitai I. Inguinal mass in a 4-month-old boy. CMAJ. 2020 Jul 20; 192(29):E845. PMID: 32690560.
      View in: PubMed
    17. Jackson L, DePas W, Morris AJ, Guttman K, Yau YCW, Waters V. Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients. J Vis Exp. 2020 07 16; (161). PMID: 32744517.
      View in: PubMed
    18. Bullington W, Hempstead S, Smyth AR, Drevinek P, Saiman L, Waters VJ, Bell SC, VanDevanter DR, Flume PA, Elborn S, Muhlebach MS. Antimicrobial resistance: Concerns of healthcare providers and people with CF. J Cyst Fibros. 2021 05; 20(3):407-412. PMID: 32563724.
      View in: PubMed
    19. Smith S, Waters V, Jahnke N, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev. 2020 06 10; 6:CD009528. PMID: 32520436.
      View in: PubMed
    20. Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev. 2020 06 10; 6:CD010004. PMID: 32521055.
      View in: PubMed
    21. Smith S, Ratjen F, Remmington T, Waters V. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2020 05 15; 5:CD006961. PMID: 32412092.
      View in: PubMed
    22. Amin R, Jahnke N, Waters V. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. Cochrane Database Syst Rev. 2020 03 18; 3:CD009249. PMID: 32189337.
      View in: PubMed
    23. Cogen JD, Kahl BC, Maples H, McColley SA, Roberts JA, Winthrop KL, Morris AM, Holmes A, Flume PA, VanDevanter DR, Waters V, Muhlebach MS, Elborn JS, Saiman L, Bell SC. Finding the relevance of antimicrobial stewardship for cystic fibrosis. J Cyst Fibros. 2020 07; 19(4):511-520. PMID: 32122785.
      View in: PubMed
    24. Khafagy R, Gupta S, Campisi P, Waters V. Treatment of localized mucormycosis using nasal amphotericin B irrigation in pediatric oncology. Pediatr Blood Cancer. 2020 04; 67(4):e28175. PMID: 31925929.
      View in: PubMed
    25. Blanchard AC, Waters VJ. Microbiology of Cystic Fibrosis Airway Disease. Semin Respir Crit Care Med. 2019 12; 40(6):727-736. PMID: 31887768.
      View in: PubMed
    26. Blanchard AC, Tang L, Tadros M, Muller M, Spilker T, Waters VJ, LiPuma JJ, Tullis E. Burkholderia cenocepacia ET12 transmission in adults with cystic fibrosis. Thorax. 2020 01; 75(1):88-90. PMID: 31732688.
      View in: PubMed
    27. Zemanick E, Burgel PR, Taccetti G, Holmes A, Ratjen F, Byrnes CA, Waters VJ, Bell SC, VanDevanter DR, Stuart Elborn J, Flume PA. Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. J Cyst Fibros. 2020 05; 19(3):370-375. PMID: 31680041.
      View in: PubMed
    28. Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Gilligan P. Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clin Infect Dis. 2019 10 30; 69(10):1812-1816. PMID: 31056660.
      View in: PubMed
    29. Klingel M, Stanojevic S, Tullis E, Ratjen F, Waters V. Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis. Ann Am Thorac Soc. 2019 07; 16(7):861-867. PMID: 30874447.
      View in: PubMed
    30. Somayaji R, Parkins MD, Shah A, Martiniano SL, Tunney MM, Kahle JS, Waters VJ, Elborn JS, Bell SC, Flume PA, VanDevanter DR. Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. J Cyst Fibros. 2019 03; 18(2):236-243. PMID: 30709744.
      View in: PubMed
    31. Layeghifard M, Li H, Wang PW, Donaldson SL, Coburn B, Clark ST, Caballero JD, Zhang Y, Tullis DE, Yau YCW, Waters V, Hwang DM, Guttman DS. Microbiome networks and change-point analysis reveal key community changes associated with cystic fibrosis pulmonary exacerbations. NPJ Biofilms Microbiomes. 2019; 5(1):4. PMID: 30675371.
      View in: PubMed
    32. Clark ST, Sinha U, Zhang Y, Wang PW, Donaldson SL, Coburn B, Waters VJ, Yau YCW, Tullis DE, Guttman DS, Hwang DM. Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with ß-lactams. Int J Antimicrob Agents. 2019 May; 53(5):620-628. PMID: 30664925.
      View in: PubMed
    33. Diaz Caballero J, Clark ST, Wang PW, Donaldson SL, Coburn B, Tullis DE, Yau YCW, Waters VJ, Hwang DM, Guttman DS. A genome-wide association analysis reveals a potential role for recombination in the evolution of antimicrobial resistance in Burkholderia multivorans. PLoS Pathog. 2018 12; 14(12):e1007453. PMID: 30532201.
      View in: PubMed
    34. Beaudoin T, Stone TA, Glibowicka M, Adams C, Yau Y, Ahmadi S, Bear CE, Grasemann H, Waters V, Deber CM. Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms. Sci Rep. 2018 10 03; 8(1):14728. PMID: 30283025.
      View in: PubMed
    35. Flume PA, Waters VJ, Bell SC, Van Devanter DR, Stuart Elborn J. Antimicrobial resistance in cystic fibrosis: Does it matter? J Cyst Fibros. 2018 11; 17(6):687-689. PMID: 30270113.
      View in: PubMed
    36. Kidd TJ, Canton R, Ekkelenkamp M, Johansen HK, Gilligan P, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Waters VJ. Defining antimicrobial resistance in cystic fibrosis. J Cyst Fibros. 2018 11; 17(6):696-704. PMID: 30266518.
      View in: PubMed
    37. Ho SSC, Nashid N, Waters VJ, LiPuma JJ, Zlosnik JEA, Otley A, Somers GR, Kamath BM, Yau YCW. Burkholderia multivorans septicemia in a pediatric liver transplant patient. Am J Transplant. 2019 03; 19(3):933-938. PMID: 30091842.
      View in: PubMed
    38. Parkins MD, Somayaji R, Waters VJ. Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis. Clin Microbiol Rev. 2018 10; 31(4). PMID: 30158299.
      View in: PubMed
    39. Yang C, Yasseen AS, Stimec J, Rea E, Waters V, Lam R, Morris SK, Kitai I. Prevalence of tuberculosis infection and disease in children referred for tuberculosis medical surveillance in Ontario: a single-cohort study. CMAJ Open. 2018 Jul-Sep; 6(3):E365-E371. PMID: 30154220.
      View in: PubMed
    40. Middleton MA, Layeghifard M, Klingel M, Stanojevic S, Yau YCW, Zlosnik JEA, Coriati A, Ratjen FA, Tullis ED, Stephenson A, Wilcox P, Freitag A, Chilvers M, McKinney M, Lavoie A, Wang PW, Guttman DS, Waters VJ. Epidemiology of Clonal Pseudomonas aeruginosa Infection in a Canadian Cystic Fibrosis Population. Ann Am Thorac Soc. 2018 07; 15(7):827-836. PMID: 29911888.
      View in: PubMed
    41. Waters V. Chronic Antibiotic Use in Cystic Fibrosis: A Fine Balance. Ann Am Thorac Soc. 2018 06; 15(6):667-668. PMID: 29856253.
      View in: PubMed
    42. Waters V, Grimwood K. Defining chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Cyst Fibros. 2018 05; 17(3):292-293. PMID: 29602718.
      View in: PubMed
    43. Downie ML, Alghounaim M, Davidge KM, Yau Y, Walsh TJ, Pope E, Somers GR, Waters V, Robinson LA. Isolated cutaneous mucormycosis in a pediatric renal transplant recipient. Pediatr Transplant. 2018 06; 22(4):e13172. PMID: 29569805.
      View in: PubMed
    44. Blanchard AC, Rooney AM, Yau Y, Zhang Y, Stapleton PJ, Horton E, Klingel M, Stanojevic S, Ratjen F, Coburn B, Waters V. Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment. J Cyst Fibros. 2018 11; 17(6):723-728. PMID: 29525410.
      View in: PubMed
    45. Kordy F, Waters V, Den-Hollander C, Read S, Lam R, Kitai I. Optimizing Blood Collection and Processing for Quantiferon-TB Gold in-Tube Testing Gives Low Rates of Indeterminate Results: Clinical Implications. Pediatr Infect Dis J. 2018 Jan; 37(1):e22-e24. PMID: 28787385.
      View in: PubMed
    46. Beaudoin T, Yau YCW, Stapleton PJ, Gong Y, Wang PW, Guttman DS, Waters V. Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance. NPJ Biofilms Microbiomes. 2017; 3:25. PMID: 29062489.
      View in: PubMed
    47. Waters V, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev. 2017 10 05; 10:CD009528. PMID: 28981972.
      View in: PubMed
    48. Singh M, Yau YCW, Wang S, Waters V, Kumar A. MexXY efflux pump overexpression and aminoglycoside resistance in cystic fibrosis isolates of Pseudomonas aeruginosa from chronic infections. Can J Microbiol. 2017 Dec; 63(12):929-938. PMID: 28922614.
      View in: PubMed
    49. Somayaji R, Stanojevic S, Tullis DE, Stephenson AL, Ratjen F, Waters V. Clinical Outcomes Associated with Achromobacter Species Infection in Patients with Cystic Fibrosis. Ann Am Thorac Soc. 2017 Sep; 14(9):1412-1418. PMID: 28406714.
      View in: PubMed
    50. Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2017 06 19; 6:CD006961. PMID: 28628280.
      View in: PubMed
    51. Waters V, Yau Y, Beaudoin T, Wettlaufer J, Tom SK, McDonald N, Rizvi L, Klingel M, Ratjen F, Tullis E. Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection. J Cyst Fibros. 2017 Jul; 16(4):492-495. PMID: 28262569.
      View in: PubMed
    52. Blanchard AC, Horton E, Stanojevic S, Taylor L, Waters V, Ratjen F. Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. J Cyst Fibros. 2017 May; 16(3):395-400. PMID: 28189634.
      View in: PubMed
    53. Chuong KH, Hwang DM, Tullis DE, Waters VJ, Yau YC, Guttman DS, O'Doherty KC. Navigating social and ethical challenges of biobanking for human microbiome research. BMC Med Ethics. 2017 01 11; 18(1):1. PMID: 28077127.
      View in: PubMed
    54. Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev. 2016 12 19; 12:CD010004. PMID: 28000919.
      View in: PubMed
    55. Beaudoin T, Kennedy S, Yau Y, Waters V. Visualizing the Effects of Sputum on Biofilm Development Using a Chambered Coverglass Model. J Vis Exp. 2016 12 14; (118). PMID: 28060284.
      View in: PubMed
    56. Waters V, Stanojevic S, Ratjen F. Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis. Expert Rev Respir Med. 2016 Nov; 10(11):1221-1228. PMID: 27718754.
      View in: PubMed
    57. Stanojevic S, McDonald A, Waters V, MacDonald S, Horton E, Tullis E, Ratjen F. Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis. Thorax. 2017 04; 72(4):327-332. PMID: 27539619.
      View in: PubMed
    58. Amin R, Waters V. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. Cochrane Database Syst Rev. 2016 Jul 14; 7:CD009249. PMID: 27415821.
      View in: PubMed
    59. Wettlaufer J, Klingel M, Yau Y, Stanojevic S, Tullis E, Ratjen F, Waters V. Longitudinal study of Stenotrophomonas maltophilia antibody levels and outcomes in cystic fibrosis patients. J Cyst Fibros. 2017 01; 16(1):58-63. PMID: 27346471.
      View in: PubMed
    60. Christofides E, Dobson JA, Solomon M, Waters V, O'Doherty KC. Heuristic decision-making about research participation in children with cystic fibrosis. Soc Sci Med. 2016 08; 162:32-40. PMID: 27328055.
      View in: PubMed
    61. Beaudoin T, Waters V. Infections With Biofilm Formation: Selection of Antimicrobials and Role of Prolonged Antibiotic Therapy. Pediatr Infect Dis J. 2016 06; 35(6):695-7. PMID: 26986772.
      View in: PubMed
    62. Vidya P, Smith L, Beaudoin T, Yau YC, Clark S, Coburn B, Guttman DS, Hwang DM, Waters V. Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2016 Jan; 35(1):67-74. PMID: 26492874.
      View in: PubMed
    63. Balwan A, Nicolau DP, Wungwattana M, Zuckerman JB, Waters V. Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient. Antimicrob Agents Chemother. 2016 01; 60(1):1-5. PMID: 26722110.
      View in: PubMed
    64. Ratjen F, Waters V, Klingel M, McDonald N, Dell S, Leahy TR, Yau Y, Grasemann H. Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J. 2016 Mar; 47(3):829-36. PMID: 26585432.
      View in: PubMed
    65. Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2015 Nov 02; (11):CD006961. PMID: 26522473.
      View in: PubMed
    66. Tom SK, Yau YC, Beaudoin T, LiPuma JJ, Waters V. Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients. Antimicrob Agents Chemother. 2016 01; 60(1):650-2. PMID: 26525791.
      View in: PubMed
    67. Waters V, Ratjen F. Pulmonary Exacerbations in Children with Cystic Fibrosis. Ann Am Thorac Soc. 2015 Nov; 12 Suppl 2:S200-6. PMID: 26595740.
      View in: PubMed
    68. Kennedy S, Beaudoin T, Yau YC, Caraher E, Zlosnik JE, Speert DP, LiPuma JJ, Tullis E, Waters V. Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms. Antimicrob Agents Chemother. 2016 01; 60(1):348-55. PMID: 26503664.
      View in: PubMed
    69. Geake JB, Reid DW, Currie BJ, Bell SC, Bright-Thomas R, Dewar J, Holden S, Simmonds N, Gyi K, Kenna D, Waters V, Jackson M, O'Sullivan B, Taccetti G, Kolbe J, O'Carroll M, Campbell D, Jaksic M, Radhakrishna N, Kidd TJ, Flight W. An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis. BMC Pulm Med. 2015 Oct 09; 15:116. PMID: 26453341.
      View in: PubMed
    70. Diaz Caballero J, Clark ST, Coburn B, Zhang Y, Wang PW, Donaldson SL, Tullis DE, Yau YC, Waters VJ, Hwang DM, Guttman DS. Selective Sweeps and Parallel Pathoadaptation Drive Pseudomonas aeruginosa Evolution in the Cystic Fibrosis Lung. mBio. 2015 Sep 01; 6(5):e00981-15. PMID: 26330513.
      View in: PubMed
    71. Waters V, Stanojevic S, Klingel M, Chiang J, Sonneveld N, Kukkar R, Tullis E, Ratjen F. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2015 Nov; 14(6):770-6. PMID: 26265220.
      View in: PubMed
    72. Clark ST, Diaz Caballero J, Cheang M, Coburn B, Wang PW, Donaldson SL, Zhang Y, Liu M, Keshavjee S, Yau YC, Waters VJ, Elizabeth Tullis D, Guttman DS, Hwang DM. Phenotypic diversity within a Pseudomonas aeruginosa population infecting an adult with cystic fibrosis. Sci Rep. 2015 Jun 05; 5:10932. PMID: 26047320.
      View in: PubMed
    73. Coburn B, Wang PW, Diaz Caballero J, Clark ST, Brahma V, Donaldson S, Zhang Y, Surendra A, Gong Y, Elizabeth Tullis D, Yau YC, Waters VJ, Hwang DM, Guttman DS. Lung microbiota across age and disease stage in cystic fibrosis. Sci Rep. 2015 May 14; 5:10241. PMID: 25974282.
      View in: PubMed
    74. Waters V, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev. 2015 Mar 05; (3):CD009528. PMID: 25741986.
      View in: PubMed
    75. Waters V, Smyth A. Cystic fibrosis microbiology: Advances in antimicrobial therapy. J Cyst Fibros. 2015 Sep; 14(5):551-60. PMID: 25737165.
      View in: PubMed
    76. Waters VJ, Stanojevic S, Sonneveld N, Klingel M, Grasemann H, Yau YC, Tullis E, Wilcox P, Freitag A, Chilvers M, Ratjen FA. Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. J Cyst Fibros. 2015 Nov; 14(6):755-62. PMID: 25690407.
      View in: PubMed
    77. Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev. 2014 Dec 03; (12):CD010004. PMID: 25470304.
      View in: PubMed
    78. Yau YC, Ratjen F, Tullis E, Wilcox P, Freitag A, Chilvers M, Grasemann H, Zlosnik J, Speert D, Corey M, Stanojevic S, Matukas L, Leahy TR, Shih S, Waters V. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. J Cyst Fibros. 2015 Mar; 14(2):262-6. PMID: 25453872.
      View in: PubMed
    79. Ratjen A, Yau Y, Wettlaufer J, Matukas L, Zlosnik JE, Speert DP, LiPuma JJ, Tullis E, Waters V. In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 2015 Jan; 59(1):711-3. PMID: 25348526.
      View in: PubMed
    80. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA. Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi. Ann Am Thorac Soc. 2014 Oct; 11(8):1298-306. PMID: 25167882.
      View in: PubMed
    81. Waters VJ, Ratjen FA. Is there a role for antimicrobial stewardship in cystic fibrosis? Ann Am Thorac Soc. 2014 Sep; 11(7):1116-9. PMID: 25102101.
      View in: PubMed
    82. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc. 2014 Sep; 11(7):1120-9. PMID: 25102221.
      View in: PubMed
    83. Waters V, Ratjen F. Inhaled liposomal amikacin. Expert Rev Respir Med. 2014 Aug; 8(4):401-9. PMID: 24882271.
      View in: PubMed
    84. Waters V. Editorial commentary: how can understanding the phenotype of Pseudomonas aeruginosa lead to more successful eradication strategies in cystic fibrosis? Clin Infect Dis. 2014 Sep 01; 59(5):632-4. PMID: 24863402.
      View in: PubMed
    85. Amin R, Waters V. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. Cochrane Database Syst Rev. 2014 Apr 02; (4):CD009249. PMID: 24696136.
      View in: PubMed
    86. Luong ML, Chaparro C, Stephenson A, Rotstein C, Singer LG, Waters V, Azad S, Keshavjee S, Tullis E, Husain S. Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantation. 2014 Feb 15; 97(3):351-7. PMID: 24305637.
      View in: PubMed
    87. Chen LY, Chen J, Waters V, Boodhan S. Incompatibility of ciprofloxacin and meropenem injections. Am J Health Syst Pharm. 2013 Nov 15; 70(22):1966, 1970. PMID: 24173004.
      View in: PubMed
    88. Stanojevic S, Waters V, Mathew JL, Taylor L, Ratjen F. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis. J Cyst Fibros. 2014 Mar; 13(2):172-8. PMID: 24091166.
      View in: PubMed
    89. Stanojevic S, Ratjen F, Stephens D, Lu A, Yau Y, Tullis E, Waters V. Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. J Cyst Fibros. 2013 Dec; 12(6):575-83. PMID: 23757360.
      View in: PubMed
    90. Wu K, Yau YC, Matukas L, Waters V. Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 2013 Mar; 57(3):1546-8. PMID: 23295930.
      View in: PubMed
    91. Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros. 2013 Sep; 12(5):482-6. PMID: 23294530.
      View in: PubMed
    92. Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev. 2012 Dec 12; 12:CD010004. PMID: 23235684.
      View in: PubMed
    93. Waters V, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev. 2012 Nov 14; 11:CD009528. PMID: 23152277.
      View in: PubMed
    94. Maughan H, Wang PW, Diaz Caballero J, Fung P, Gong Y, Donaldson SL, Yuan L, Keshavjee S, Zhang Y, Yau YC, Waters VJ, Tullis DE, Hwang DM, Guttman DS. Analysis of the cystic fibrosis lung microbiota via serial Illumina sequencing of bacterial 16S rRNA hypervariable regions. PLoS One. 2012; 7(10):e45791. PMID: 23056217.
      View in: PubMed
    95. Waters V, Zlosnik JE, Yau YC, Speert DP, Aaron SD, Guttman DS. Comparison of three typing methods for Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2012 Dec; 31(12):3341-50. PMID: 22843295.
      View in: PubMed
    96. Amin R, Waters V. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. Cochrane Database Syst Rev. 2012 May 16; (5):CD009249. PMID: 22592739.
      View in: PubMed
    97. Asner S, Waters V, Solomon M, Yau Y, Richardson SE, Grasemann H, Gharabaghi F, Tran D. Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros. 2012 Sep; 11(5):433-9. PMID: 22579414.
      View in: PubMed
    98. Warren TA, Yau Y, Ratjen F, Tullis E, Waters V. Serum galactomannan in cystic fibrosis patients colonized with Aspergillus species. Med Mycol. 2012 Aug; 50(6):658-60. PMID: 22524639.
      View in: PubMed
    99. Waters V. New treatments for emerging cystic fibrosis pathogens other than Pseudomonas. Curr Pharm Des. 2012; 18(5):696-725. PMID: 22229574.
      View in: PubMed
    100. Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J. 2012 Jul; 40(1):61-6. PMID: 22135280.
      View in: PubMed
    101. Waters V, Atenafu EG, Salazar JG, Lu A, Yau Y, Matukas L, Tullis E, Ratjen F. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J Cyst Fibros. 2012 Jan; 11(1):8-13. PMID: 21849265.
      View in: PubMed
    102. Leahy TR, Yau YC, Atenafu E, Corey M, Ratjen F, Waters V. Epidemiology of borderline oxacillin-resistant Staphylococcus aureus in pediatric cystic fibrosis. Pediatr Pulmonol. 2011 May; 46(5):489-96. PMID: 21337531.
      View in: PubMed
    103. Massam J, Bitnun A, Solomon M, Somers GR, Guerguerian AM, van Wylick R, Waters V. Invasive aspergillosis in cystic fibrosis: a fatal case in an adolescent and review of the literature. Pediatr Infect Dis J. 2011 Feb; 30(2):178-80. PMID: 20823780.
      View in: PubMed
    104. Waters V, Yau Y, Prasad S, Lu A, Atenafu E, Crandall I, Tom S, Tullis E, Ratjen F. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med. 2011 Mar 01; 183(5):635-40. PMID: 20889901.
      View in: PubMed
    105. Al-Saleh S, Dell SD, Grasemann H, Yau YC, Waters V, Martin S, Ratjen F. Sputum induction in routine clinical care of children with cystic fibrosis. J Pediatr. 2010 Dec; 157(6):1006-1011.e1. PMID: 20630539.
      View in: PubMed
    106. Waters V, Jamieson F, Richardson SE, Finkelstein M, Wormsbecker A, Halperin SA. Outbreak of atypical pertussis detected by polymerase chain reaction in immunized preschool-aged children. Pediatr Infect Dis J. 2009 Jul; 28(7):582-7. PMID: 19561423.
      View in: PubMed
    107. Greenberg DP, Doemland M, Bettinger JA, Scheifele DW, Halperin SA, Waters V, Kandola K. Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States. Pediatr Infect Dis J. 2009 Jun; 28(6):521-8. PMID: 19436236.
      View in: PubMed
    108. Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2008 Jul 16; (3):CD006961. PMID: 18646176.
      View in: PubMed
    109. Corral DM, Coates AL, Yau YC, Tellier R, Glass M, Jones SM, Waters VJ. Burkholderia pseudomallei infection in a cystic fibrosis patient from the Caribbean: a case report. Can Respir J. 2008 Jul-Aug; 15(5):237-9. PMID: 18716683.
      View in: PubMed
    110. Lam W, Tjon J, Seto W, Dekker A, Wong C, Atenafu E, Bitnun A, Waters V, Yau Y, Solomon M, Ratjen F. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. J Antimicrob Chemother. 2007 Jun; 59(6):1135-40. PMID: 17446242.
      View in: PubMed
    111. Waters VJ, Gómez MI, Soong G, Amin S, Ernst RK, Prince A. Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia. Infect Immun. 2007 Apr; 75(4):1698-703. PMID: 17220304.
      View in: PubMed
    112. Waters V, Ratjen F. Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues. Expert Rev Anti Infect Ther. 2006 Oct; 4(5):807-19. PMID: 17140357.
      View in: PubMed
    113. Barton M, Hawkes M, Moore D, Conly J, Nicolle L, Allen U, Boyd N, Embree J, Van Horne L, Le Saux N, Richardson S, Moore A, Tran D, Waters V, Vearncombe M, Katz K, Weese JS, Embil J, Ofner-Agostini M, Ford-Jones EL. Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: A perspective for Canadian health care practitioners. Can J Infect Dis Med Microbiol. 2006 Sep; 17 Suppl C:4C-24C. PMID: 23365589.
      View in: PubMed
    114. Waters V, Peterson KS, LaRussa P. Live viral vaccines in a DiGeorge syndrome patient. Arch Dis Child. 2007 Jun; 92(6):519-20. PMID: 16798784.
      View in: PubMed
    115. Waters V, Sokol S, Reddy B, Soong G, Chun J, Prince A. The effect of cyclosporin A on airway cell proinflammatory signaling and pneumonia. Am J Respir Cell Mol Biol. 2005 Aug; 33(2):138-44. PMID: 15879161.
      View in: PubMed
    116. Waters V, Larson E, Wu F, San Gabriel P, Haas J, Cimiotti J, Della-Latta P, Saiman L. Molecular epidemiology of gram-negative bacilli from infected neonates and health care workers' hands in neonatal intensive care units. Clin Infect Dis. 2004 Jun 15; 38(12):1682-7. PMID: 15227612.
      View in: PubMed
    117. Waters V, Ford-Jones EL, Petric M, Fearon M, Corey P, Moineddein R. Etiology of community-acquired pediatric viral diarrhea: a prospective longitudinal study in hospitals, emergency departments, pediatric practices and child care centers during the winter rotavirus outbreak, 1997 to 1998. The Pediatric Rotavirus Epidemiology Study for Immunization Study Group. Pediatr Infect Dis J. 2000 Sep; 19(9):843-8. PMID: 11001107.
      View in: PubMed
    Waters's networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description